Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016

Supporting Information for:

Efficient Construction of Biologically Important Functionalized Polycyclic Spirofused Carbocyclicoxindoles via an Asymmetric Organocatalytic Quadruple-Cascade Reaction

Wen Ren,^{a,d} Xiao-Yan Wang,^{b,d} Jing-Jing Li,^a Mao Tian,^a Jie Liu,^{a,*} Liang Ouyang,^a Jin-Hui Wang^{c,*}

a. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. Fax: (+86)-028-8550-3817; phone: (+86)-028-8550-3817; E-mail: liujie2011@scu.edu.cn, hegusc2015@163.com

b. Analytical & Testing Center, Sichuan University, Chengdu 610064, China

c. College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China. Email: wangjinhui2015@sina.com

d. Contribute equally

Contents:

(A) General Information	S2
(B) Representative Procedure for the Asymmetric Catalysis	S2
(C) Tables for the Optimization of the Reaction Conditions	S3
(D) Tables for the Investigation of Substrate Scope	S7
(E) Synthesis of several Substituted Oxindole	S12
(F) Synthesis of Substituted (<i>E</i>)-3-(2-hydroxybenzylidene)Oxindole	S12
(G) Biological Activity study	S12
(H) Analytical and Spectral Characterization Data	S15
(I) References	S39
(J) Copies of NMR Spectra	S40
(K) Crystal Structure and data for compound 5ka	

(A) General Information.

NMR spectra were recorded on the commercial 400 MHz spectrometer. The chemical shifts were recorded in ppm relative to tetramethylsilane (TMS) and with the solvent resonance as the internal standard. ¹H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, dq = doublet of quartet), coupling constants (Hz), integration. ¹³C NMR data were collected at 100 MHz with complete proton decoupling. Enantiomeric excesses (ee) were determined by chiral HPLC analysis on DAICEL CORPORATION AS-H and AD-H columns in comparison with the authentic racemates. Optical rotations were reported as follows: $[\alpha]_D^T$ (c: g/100 mL, in solvent). ESI-HRMS spectra were recorded on a commercial apparatus and methanol was used to dissolve the sample. Substituted (E)-3-(2hydroxybenzylidene)oxindole 1 were prepared by Knoevenagel condensation of corresponding Salicylaldehyde derivatives and Oxindole derivatives.¹ α , β -unsaturated aldehydes 2, diphenylprolinol silvl ether catalysts 3, additives 4 and solvents were commercially available and used directly without further purification. Several substituted oxindoles were prepared according to the literatures and references therein.²

(B) Representative Procedure for the Asymmetric Catalysis

1. Procedure for the optimization of reaction conditions

Crotonaldehyde **2a** (0.244 mmol, 20 μ L) was added to a dry tube containing a suspension of (*E*)-3-(2-hydroxybenzylidene)oxindole **1a** (0.1 mmol), chiral diphenylprolinol silyl ether catalyst **3** (20 mol %), addtive **4** and dry solvent 1 mL. The mixture was stirred at 40 °C or 60 °C. The reaction progress was detected by TLC. After the time indicated in Tables, reaction mixture was subjected to silica gel column chromatography to yield the corresponding product (petroleum ether/ ethyl acetate, 2/1, *V/V*).

2. Procedure for the investigation of substrate scope

α, β-unsaturated aldehydes **2** (0.244 mmol) was added to a dry tube containing a suspension of substituted (*E*)-3-(2-hydroxybenzylidene)oxindole **1** (0.1 mmol), α,α-L-diphenylprolinol trimethylsilyl ether **3a** (20 mol%), 2-(trifluoromethyl)benzoic acid **4h** (60 mol%) and CHCl₃ 1 mL. The mixture was stirred at 40 °C for 24 h and then heated up to 60 °C for 12 h. The reaction mixture was subjected to silica gel column

chromatography to yield the corresponding product (generally petroleum ether/ ethyl acetate, 2/1, V/V; for **5ia**: dichloromethane/ethyl acetate, 30/1, V/V; for **5ma**: petroleum ether/ethyl acetate, 3/1, V/V; for **5ma**: dichloromethane/methanol, 100/1, V/V; for **5ta**: petroleum ether/ethyl acetate, 7/1, V/V).

(C) Tables for the Optimization of the Reaction Conditions

1. Investigation of structures of chiral diphenylprolinol silyl ether catalysts on results



^a Reactions were performed with 0.1 mmol **1a** and 0.244 mmol (20 μ L) **2a** in the presence of catalyst **3** (20 mol %) and the additive AcOH **4a** (20 mol %) in CHCl₃ at 60 °C for 12 h.

^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

Trace: little products were detected. n.d.: not determined.

2. The influence of additives on the result^a



Table S2. The influence of additives^a

Entry	Addtive	Yield (%) ^b	Dr ^c	Ee(%) ^d
1	4a	60	1:1	98; 90
2	4b	Traces	n.d.	n.d.
3	4c	Traces	n.d.	n.d.
4	4d	Traces	n.d.	n.d.
5	4e	63	1:1	98; 93
6	4f	65	1:1	98; 94
7	4g	61	1:1	98; 91
8	4h	68	2:1	>99; 94
9	4i	58	1:1	97; 93

^a Reactions were performed with 0.1 mmol **1a** and 0.244 mmol (20 μ L) **2a** in the presence of the catalyst **3a** (20 mol%) and additive **4** (20 mol%) in CHCl₃ at 60 °C for 12h.

^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

N.D.: not detected. Trace: little products were detected.

3. Solvent effect^a



Entry	Solvent	Yield (%) ^b	Dr ^c	Ee(%) ^d
1	МеОН	n.r.	n.d.	n.d.
2	EtOH	n.r.	n.d.	n.d.
3	THF	n.r.	n.d.	n.d.
4	dioxane	n.r.	n.d.	n.d.
5	anisole	44	1:2	>99; 92
6	MTBE	n.r.	n.d.	n.d.
7	toluene	55	1:1	>99; 92
8	MeCN	n.r.	n.d.	n.d.
9	EA	n.r.	n.d.	n.d.
10	DMF	n.r.	n.d.	n.d.

Table S3. The influence of solvent^a

	11	CHCl ₃	68	2:1	>99; 94
--	----	-------------------	----	-----	---------

^a Reactions were performed with 0.1 mmol **1a** and 0.244 mmol (20 μ L) **2a** in the presence of the catalyst **3a** (20 mol %) and the additive **4h** (20 mol %) in solvent at 60 °C for 12 h.

^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

n.r. : no reaction. n.d.: not detected.

4. Investigation of the dosage of additive^a



Entry	Additive dosage	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	20 mol %	68	2:1	>99; 94
2	40 mol %	71	2:1	>99; 87
3	60 mol %	83	3:1	99; 85
4	80 mol %	81	2.4:1	97; 80
5	100 mol %	83	2.3:1	95; 75
6	200 mol %	67	1.5:1	96; 78

Table S4. Investigation of the dosage of additive^a

^a Reactions were performed with 0.1 mmol **1a** and 0.244 mmol (20 μ L) **2a** in the presence of the catalyst **3a** (20 mol %) and the additive **4h** (X mol %) in CHCl₃ at 60 °C for 12 h.

^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

5. Reaction time and temperature optimization^a



Table 55. Reaction time and temperature optimization						
Entry	Temperature (°C)	Time (h)	Yield (%) ^b	Dr ^c	Ee(%) ^d	
1	60	12	83	3:1	99; 85	
2	40	60	72	6:1	97; n.d.	
3	25	168	67	5:1	>99; n.d.	
4 ^e	40→60	36	80	8:1	>99; n.d.	

Table S5. Reaction time and temperature optimization^a

^a Reactions were performed with 0.1 mmol **1a** and 0.244 mmol (20 μ L) **2a** in the presence of the catalyst **3a** (20 mol %) and the additive **4h** (60 mol %) in CHCl₃. ^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

^e The reaction was conducted at 40 °C for 24 h , then heated up to 60 °C for 12 h.

The optimal conditions: in the presence of the catalyst **3a** (20 mol %) and the additive **4h** (60 mol%), 0.1 mmol **1a** and 0.244 mmol **2a** was stirred in CHCl₃ 1mL at 40 °C for 24h and then heated up to 60 °C for 12 h.

(D) Tables for the Investigation of Substrate Scope^a

Table S6. The investigation of substrate scope						
Entry	1	2	5	Yield (%) ^b	Dr ^c	Ee (%) ^d







80

2





6:1

>99

3



1c

1d

OH

=0

OH

=O

Ň

1e

0 ||

2a





4













72



8



7





70

65

67

80

ő





OH

=0

-OH

=O

2a

Ň











1:4

>99







5ib







2a





98

6:1



10











13

15





5ma

45

83









Ο

OH

C

0

2b

Ň

10

'N H

0



16 **1**a



1:2.5 64

2.5:1

>99



^a Reactions were performed with 0.1 mmol **1** and 0.244 mmol **2** in the presence of the catalyst **3a** (20 mol %) and the additive **4h** (60 mol %) in CHCl₃ 1 mL at 40 °C for 24 h and then heated up to 60 °C for 12 h.

^b The values are yields of isolated product after silica gel column chromatography.

^c Determined by ¹H NMR on the crude reaction mixture.

^d Determined by chiral HPLC.

^e only one molecule of **2e** was involved in the reaction at 40 °C for 24h to generate **5sa**.

^f only one molecule of **2a** was employed in the reaction at 60 °C for 12h to generate **5s**.

(E) Synthesis of several Substituted Oxindole.

Substituted Isatin (10 mmol) was dissolved in hydrazine hydrate (98%, 10 mL, 32.5 mmol) and refluxed for 15-30 min (130 °C). The reaction mixture was then poured in cold water, extracted with EtOAc and the organic layer was dried over Na₂SO₄. Evaporation of the solvent and recrystallization from hexane/ethyl acetate afforded substituted oxindole.

(F) Synthesis of Substituted (E)-3-(2-hydroxybenzylidene)Oxindole.

A reaction mixture of substituted oxindole (1 equiv), substituted salicylaldehyde (1.2 equiv) and piperidine (0.1 equiv) in ethanol (1-2 mL/1 mmol) was stirred at 90 °C for 3-5 h. After cooled down, the precipitate was filtered and washed with cold ethanol and diethyl ether, successively. Allowed to dry, it was used in subsequent reaction without further purification.

(G) Biological Activity study

Anti-tumor assay

Briefly, targeted cancer cells lines (3×10^3 /well) were seeded in 96-well plates and cultured for 24 h, followed by compounds treatment for 24 h. A volume of 20 µL of 5 mg/mL MTT was added per well and incubated for another 4 h at 37 °C, then the supernatant fluid was removed and DMSO was added 150 µL /well for 15-20 min. The absorptions (OD) were measured at 570 nm with Spectra MAX M5 microplate spectrophotometer (Molecular Devices). The effect of compounds on tumor cells viability was expressed by cell growth inhibitory rate at 30 µM or IC₅₀ of each cell line. Each assay was carried out at least three times. The results are summarized in **Table S7** and **Table S8**.

Table S7. Cellular evaluation of the polycyclic spiro-fused carbocyclicoxindoles 5 against cancer cell-line MCF-7 (cell growth inhibitory rate at 30 μM)^a

Entry	Compound	Inhibition	rate	of	anticancer	cells
		proliferation	ı (%)			
1	5aa	35.78				
2	5ba	29.19				

3	5ca	36.31
4	5da	48.72
5	5ea	39.11
6	5fa	68.25
7	5ga	44.55
8	5ha	45.64
9	5ia	99.95
10	5ja	41.57
11	5ka	13.45
12	5la	83.29
13	5ma	41.78
14	5na	89.02
15	50a	19.68
16	5pa	64.98
17	5qa	34.20
18	5ra	81.72
19	5sa	31.97

^a Inhibition rate values were measured by an MTT assay upon 24 h drug treatment. Values were obtained through independent measurement of cell viabilities.

Table S8. Cellular evaluation of the the polycyclic spiro-fused carbocyclicoxindole 5ia against diverse cancer cell-lines (IC₅₀ in μ M)^a

Entry	Cell lines	IC ₅₀ (μM)
1	MCF-7	9.2
2	MDA-MB-231	11.5
3	H1975	14.1
4	FaDu	13.7

a Values were average of three determinations and deviation from the average is <5% of the average value

(H) Analytical and Spectral Characterization Data



¹H NMR (400 MHz, DMSO) $\delta = 10.57$ (s, 1H), 10.19 (s, 1H), 7.69 (s, 1H), 7.64-7.63 (m, 1H), 7.51-7.49 (m, 1H), 7.34-7.30 (m, 1H), 7.23-7.19 (m, 1H), 6.99-6.95(m, 1H), 6.93-6.91 (m, 1H), 6.88-6.83 (m, 2H). ¹³C NMR (100 MHz, DMSO) $\delta = 168.8$, 156.5, 142.6, 132.4, 131.6, 129.6, 129.5, 126.4, 122.3, 121.3, 121.2, 121.0, 118.8, 115.9, 109.9.



^{1b} ¹H NMR (400 MHz, DMSO) δ = 10.61 (s, 1H), 10.28 (s, 1H), 7.65 (s, 1H), 7.45-7.42 (m, 2H), 7.32-7.21 (m, 2H), 6.97-6.83 (m, 3H). ¹³C NMR (100 MHz, DMSO) δ = 168.5, 151.7(d, *J* = 238 Hz), 143.7 (d, *J* = 15 Hz), 142.8, 130.8(d, *J* = 3 Hz), 130.0, 127.7, 124.9 (d, *J* = 3 Hz), 124.7 (d, *J* = 3 Hz), 122.5, 121.0, 120.9, 119.1(d, *J* = 7 Hz), 117.2 (d, *J* = 19 Hz), 110.0.



¹H NMR (400 MHz, DMSO) δ = 10.50 (s, 1H), 10.35 (s, 1H), 7.68

(s, 1H), 7.65-7.58 (m, 2H), 7.19-7.17 (m, 1H), 6.88-6.85 (m, 2H), 6.58-6.52 (m, 2H), 3.79 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ = 169.1, 162.3, 158.4, 142.2, 132.4, 130.6, 129.1, 124.2, 121.9, 121.5, 120.9, 114.1, 109.8, 105.2, 101.1, 55.2.



^{1d} ¹H NMR (400 MHz, DMSO) δ = 10.61 (s, 1H), 10.21 (s, 1H), 7.59 (s, 1H), 7.45-7.28 (m, 2H), 7.25-7.14 (m, 2H), 6.99-6.96 (m, 1H), 6.90-6.87 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ = 168.6, 154.7(d, J = 238 Hz), 152.7 (d, J = 1.2 Hz), 142.8, 130.9, 130.0, 127.6, 122.5, 122.1 (d, J = 8 Hz), 121.1, 120.9, 117.8 (d, J = 23 Hz), 117.0 (d, J = 8 Hz), 115.2 (d, J = 23 Hz), 110.0.



1e

¹H NMR (400 MHz, DMSO) δ = 10.61 (s, 1H), 10.49 (s, 1H),

7.60-7.56 (m, 2H), 7.39-7.34 (m, 2H), 7.25-7.21 (m, 1H), 7.00-6.98 (m, 1H), 6.90-6.87 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ = 168.5, 155.2, 142.9, 130.8, 130.6, 130.1, 128.6, 127.7, 123.1, 122.3, 122.2, 121.1, 120.9, 117.6, 110.1.



¹H NMR (400 MHz, DMSO) δ = 10.61 (s, 1H), 10.53 (s, 1H),

7.73-7.72 (m, 1H), 7.56 (s, 1H), 7.49-7.46 (m, 1H), 7.39-7.37 (m, 1H), 7.25-7.21 (m, 1H), 6.96-6.87 (m, 3H). ¹³C NMR (100 MHz, DMSO) δ = 168.4, 155.6, 142.9, 133.6, 131.4, 130.5, 130.1, 127.7, 123.7, 122.2, 122.5, 121.1, 120.9, 118.1, 110.1, 109.6.



^{1g} ¹H NMR (400 MHz, DMSO) δ = 10.67 (s, 1H), 8.51-8.50 (m, 1H), 8.24-8.21 (m, 1H), 7.58 (s, 1H), 7.44-7.42 (m, 1H), 7.27-7.23 (m, 1H), 7.16-7.14 (m, 1H), 6.91-6.84 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ = 168.3, 162.4, 143.1, 139.2, 130.4, 129.4, 128.6, 127.0, 125.5, 122.5, 121.8, 121.3, 120.6, 116.3, 110.2



^{1h} ¹H NMR (400 MHz, DMSO) δ = 10.55 (s, 1H), 9.94 (s, 1H), 7.67 (s, 1H), 7.52-7.51 (m, 1H), 7.43 (s, 1H), 7.23-7.19 (m, 1H), 7.14-7.11 (m, 1H), 6.89-6.84 (m, 3H). ¹³C NMR (100 MHz, DMSO) δ = 168.8, 154.2, 142.5, 132.6, 132.1, 129.6, 129.5, 127.3, 126.3, 122.2, 121.3, 121.0, 115.8, 109.9, 20.0.



1i

¹H NMR (400 MHz, DMSO) δ = 10.61 (s, 1H), 10.34 (s, 1H),

7.93-7.89 (m, 2H), 7.85 (s, 1H), 7.59-7.57 (m, 1H), 7.43-7.37 (m, 1H), 7.35-7.30 (m, 2H), 7.15-7.11 (m, 1H), 6.86-6.84 (m, 1H), 6.66-6.62 (m, 1H), 6.39-6.37 (m, 1H). ¹³C NMR (100 MHz, DMSO) δ = 168.4, 153.7, 142.5, 131.4, 131.0, 129.6, 129.5, 129.3, 128.6, 127.6, 127.1, 124.1, 123.7, 123.2, 121.7, 120.8, 118.1, 113.7, 109.5.



¹H NMR (400 MHz, DMSO) δ = 10.46 (s, 1H), 10.17 (s, 1H),

7.66 (s, 1H), 7.64-7.62 (m, 1H), 7.34-7.30 (m, 2H), 7.04-6.92 (m, 3H), 6.77-6.75(m, 1H), 2.16 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ = 168.8, 156.5, 140.3, 132.2, 131.6, 130.1, 129.5, 126.6, 122.8, 121.4, 121.3, 118.7, 115.9, 109.6, 20.8.



^{1k} ¹H NMR (400 MHz, DMSO) δ = 10.60 (s, 1H), 10.29 (s, 1H), 7.76 (s, 1H), 7.61-7.59 (m, 1H), 7.37-7.33 (m, 1H), 7.19-7.17 (m, 1H), 7.09-7.04 (m, 1H), 7.02-6.94 (m, 2H), 6.88-6.84 (m, 1H). ¹³C NMR (100 MHz, DMSO) δ = 168.7, 157.1 (d, *J* = 235 Hz), 156.5, 138.9, 134.1, 132.0, 129.5, 126.3 (d, *J* = 3 Hz), 122.3 (d, *J* = 9 Hz), 120.9, 118.9, 116.1, 115.8 (d, *J* = 24 Hz), 110.5 (d, *J* = 8 Hz), 109.4 (d, *J* = 26 Hz).



¹H NMR (400 MHz, DMSO) δ = 10.73 (s, 1H), 10.27 (s, 1H),

7.74 (s, 1H), 7.61-7.59 (m, 1H), 7.48-7.46 (m, 1H), 7.35-7.31 (m, 1H), 7.00-6.98 (m, 1H), 6.94-6.88 (m, 3H). ¹³C NMR (100 MHz, DMSO) δ = 168.7, 156.6, 143.9, 133.6, 133.3, 131.9, 129.5, 125.3, 123.5, 121.0, 120.8, 120.2, 118.9, 116.0, 109.9.



¹H NMR (400 MHz, DMSO) δ = 10.23 (s, 1H), 7.78 (s, 1H), 7.64-

7.62 (m, 1H), 7.55-7.53 (m, 1H), 7.35-7.29 (m, 2H), 7.04-6.98 (m, 2H), 6.95-6.91 (m, 2H), 3.21 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ = 167.3, 156.5, 143.7, 133.0, 131.7, 129.7, 129.6, 125.5, 122.0, 121.5, 121.2, 120.5, 118.8, 116.0, 108.7, 25.9.



¹H NMR (400 MHz, DMSO) δ = 10.30 (s, 1H), 7.88 (s, 1H), 7.71-

7.69 (m, 1H), 7.65-7.58 (m, 3H), 7.50-7.47 (m, 3H), 7.38-7.35 (m, 1H), 7.28-7.24 (m, 1H), 7.03-6.95 (m, 3H), 6.79-6.77 (m, 1H). 13C NMR (100 MHz, DMSO) δ = 166.8, 156.6, 143.3, 134.3, 134.1, 131.9, 129.7, 129.6, 128.0, 126.9, 125.1, 122.4, 122.2, 121.1, 120.7, 118.9, 116.1, 109.1.



10

¹H NMR (400 MHz, DMSO) δ = 10.51 (s, 1H), 7.57 (s, 1H), 7.48-

7.42 (m, 2H), 7.21-7.14 (m, 2H), 6.87-6.77(m, 3H), 6.65-6.61 (m, 1H), 5.52 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ = 168.9, 147.9, 142.3, 133.2, 131.1, 129.3, 129.2, 126.0, 122.3, 121.6, 120.8, 117.9, 115.6, 115.5, 109.7.



^{1t} ¹H NMR (400 MHz, DMSO) δ = 10.89 (s, 1H), 8.91-8.89 (m, 1H), 8.33 (s, 1H), 7.96-7.95 (m, 4H), 7.49-7.45 (m, 1H), 7.02-6.94 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ = 189.9, 188.8, 160.0, 141.8, 139.8, 139.3, 136.0, 135.8, 135.6, 133.1, 127.1, 122.9, 122.8, 119.9, 119.0, 116.0.

6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5aa)



5aa light yellow solid; 80% yield; >99% ee; 8 : 1 dr; m.p. 125 °C - 127 °C; $[α]_D^{22} = -49.8$ (c = 1.53 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2-propanol/n-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 13.69 min (major) and 17.80 min (minor); ¹H NMR (400 MHz, CDCl₃) $\delta = 9.53$ (s, 1H), 8.86 (s, 1H), 7.28 (s, 1H), 7.13 (d, J = 7.2 Hz, 1H), 6.98 (t, J = 7.2 Hz, 2H), 6.90 (d, J = 7.6 Hz, 1H), 6.86-6.73 (m, 2H), 6.41 (t, J = 7.6 Hz, 1H), 5.99 (d, J = 7.6 Hz, 1H), 4.40 (dq, J = 11.6, 6.0 Hz, 1H), 3.67 (d, J = 10.4 Hz, 1H), 3.21 (t, J = 10.4 Hz, 1H), 2.81 (q, J = 6.4 Hz, 1H), 1.60 (d, J = 6.0 Hz, 3H), 1.19 (d, J = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 193.0$, 179.1, 154.6, 147.0, 143.7, 140.0, 131.0, 128.6, 127.9, 126.0, 125.8, 124.2, 122.1, 120.4, 117.2, 110.2, 77.7, 50.6, 44.0, 36.5, 34.8, 20.8, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₁NO₃ [M+Na]⁺ = 382.1414, Found 382.1415.





4-fluoro-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-

10,3'-indoline]-8-carbaldehyde (5ba)



5ba White solid; 75% yield; >99% ee; 6:1 dr; m.p. 59 °C-61 °C; [α]_D²² = -50.0 (c = 0.074 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 15/85, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 11.99 min (major) and 14.07 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 7.95 (s, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.17 (d, *J* = 7.6 Hz, 1H), 7.07-6.94 (m, 2H), 6.88-6.77 (m, 2H), 6.37 (td, *J* = 8.0, 5.2 Hz, 1H), 5.79 (d, *J* = 8.0 Hz, 1H), 4.48 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.69 (d, *J* = 10.4 Hz, 1H), 3.24 (t, *J* = 10.8 Hz, 1H), 2.84 (q, *J* = 6.8 Hz, 1H), 1.68 (d, *J* = 6.0 Hz, 3H), 1.21 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.9, 179.3, 146.3, 143.8, 142.7, 140.0, 130.8, 128.7, 128.3, 125.9, 122.2, 119.9, 119.3, 114.8, 114.6, 110.4, 78.3, 50.7, 43.9, 36.5, 34.8, 20.7, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₀FNO₃ [M+Na]⁺ = 400.1319, Found 400.1325.



3-methoxy-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-

10,3'-indoline]-8-carbaldehyde (5ca)



5ca light yellow solid; 65% yield; >99% ee; 5:1 dr; m.p.70 °C-72 °C; [α]_D²² = -42.3 (c = 0.40 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 17.63 min (major) and 21.38 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.53 (s, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.03 (t, *J* = 7.6 Hz, 1H), 6.96 (d, *J* = 7.6 Hz, 1H), 6.83 (d, *J* = 2.4 Hz, 1H), 6.38 (d, *J* = 2.4 Hz, 1H), 6.00 (dd, *J* = 8.8, 2.4 Hz, 1H), 5.88 (d, *J* = 8.8 Hz, 1H), 4.38 (dq, *J* = 12.2, 6.0 Hz, 1H), 3.65 (s, 4H), 3.23 (t, *J* = 10.4 Hz, 1H), 2.81 (q, *J* = 6.8 Hz, 1H), 1.62 (d, *J* = 6.0 Hz, 3H), 1.19 (d, *J* = 4.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.0, 179.4, 159.5, 155.7, 146.9, 143.9, 140.1, 131.1, 128.6, 126.0, 124.9, 122.1, 117.5, 110.3, 106.0, 102.8, 77.6, 55.2, 50.9, 44.0, 36.1, 34.7, 20.7, 19.0. HRMS (ESI-TOF) calcd for C₂₄H₂₃NO₄ [M+Na]⁺ = 412.1519, Found 412.1533.



2-fluoro-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5da)



5da White solid; 72% yield; 98% ee; 7:1 dr; m.p. 61 °C-63 °C; $[α]_D^{22}$ = -24.5 (c = 0.33 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 15.51 min (major) and 18.96 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.53 (s, 1H), 8.00 (s, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.08-6.97 (m, 2H), 6.81 (d, *J* = 2.4 Hz, 1H), 6.76-6.66 (m, 2H), 5.73 (dd, *J* = 10.0, 2.4 Hz, 1H), 4.37 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.64 (d, *J* = 10.4 Hz, 1H), 3.18 (t, *J* = 10.8 Hz, 1H), 2.83 (q, *J* = 6.8 Hz, 1H), 1.59 (d, *J* = 6.0 Hz, 3H), 1.21 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.9, 179.2, 150.6, 146.6, 143.7, 140.1, 130.4, 129.0, 127.1, 127.1, 126.0, 122.3, 117.9, 117.8, 114.3, 114.1, 111.5, 111.3, 110.6, 77.5, 50.6, 43.8, 36.5, 34.8, 20.7, 18.8. HRMS (ESI-TOF) calcd for C₂₃H₂₀FNO₃ [M+Na]⁺ = 400.1319, Found 400.1329.



2-chloro-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5ea)



5ea White solid; 65% yield; 98% ee; 6:1 dr; m.p. 54 °C-56 °C; $[α]_D^{22}$ = -61.3 (c = 0.266 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 31.17 min (major) and 39.05 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.53 (s, 1H), 7.36 (t, *J* = 7.6 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.10-6.99 (m, 2H), 6.95 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.82 (d, *J* = 2.4 Hz, 1H), 6.72 (d, *J* = 8.4 Hz, 1H), 5.94 (d, *J* = 1.2 Hz, 1H), 4.38 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.63 (d, *J* = 10.4 Hz, 1H), 3.21 (t, *J* = 10.4 Hz, 1H), 2.84 (q, *J* = 6.8 Hz, 1H), 1.60 (d, *J* = 6.0 Hz, 3H), 1.21 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 192.9, 178.8, 153.3, 146.3, 143.8, 140.1, 130.4, 129.0, 127.8, 126.9, 126.0, 125.0, 124.7, 122.3, 118.3, 110.4, 77.7, 50.5, 43.5, 36.5, 34.7, 20.6, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₀CINO₃ [M+Na]⁺ = 416.1024, Found 416.1033.



2-bromo-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-

10,3'-indoline]-8-carbaldehyde (5fa)



5fa White solid; 70% yield; 98% ee; 7:1 dr; m.p. 94 °C-96 °C; $[\alpha]_D^{22}$ = -72.6 (c = 1.15 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 32.81 min (major) and 37.87 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 7.70 (s, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.12-7.00 (m, 3H), 6.82 (d, J = 2.4 Hz, 1H), 6.67 (d, J = 8.8 Hz, 1H), 6.08 (d, J = 1.2 Hz, 1H), 4.38 (dq, J = 12.0, 6.0 Hz, 1H), 3.64 (d, J = 10.4 Hz, 1H), 3.21 (t, J = 11.2 Hz, 1H), 2.85 (q, J = 6.8 Hz, 1H), 1.61 (d, J = 6.0 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 192.9, 178.9, 153.8, 146.3, 143.8, 140.0, 130.7, 130.4, 129.0, 127.7, 127.3, 126.0, 122.4, 118.7, 112.4, 110.4, 77.7, 50.6, 43.4, 36.5, 34.6, 20.6, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₀BrNO₃ [M+Na]⁺ = 460.0519, Found 460.0525.$



6,9-dimethyl-2-nitro-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'indoline]-8-carbaldehyde (5ga)



5ga White solid; 35% yield; 98% ee; 4:1 dr; m.p. 104 °C-106 °C; [α]_D²² = -87.1 (c = 0.31 in CHCl₃); HPLC (DAICEL CORPORATION AD-H), 2propanol/*n*-hexane = 20/80, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 11.05 min (major) and 17.27 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.58 (s, 1H), 7.93 (dd, *J* = 9.2, 2.4 Hz, 1H), 7.78 (s, 1H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 7.17-7.07 (m, 2H), 7.04 (d, *J* = 1.6 Hz, 1H), 6.86 (d, *J* = 8.8 Hz, 2H), 4.53 (dq, *J* = 12.4, 6.0 Hz, 1H), 3.70 (d, *J* = 10.4 Hz, 1H), 3.31 (t, *J* = 10.8 Hz, 1H), 2.92 (q, *J* = 6.8 Hz, 1H), 1.71 (d, *J* = 6.0 Hz, 3H), 1.26 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.7, 178.7, 160.4, 145.0, 144.3, 140.9, 140.3, 129.9, 129.4, 125.8, 125.0, 124.3, 122.5, 121.7, 117.3, 111.1, 79.0, 50.5, 42.7, 36.6, 34.4, 20.4, 19.1. HRMS (ESI-TOF) calcd for C₂₃H₂₀N₂O₅ [M+Na]⁺ = 427.1264, Found 427.1277.



2,6,9-trimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'indoline]-8-carbaldehyde (5ha)



5ha White solid; 75% yield; >99% ee; 5:1 dr; m.p. 75 °C-77 °C; [α]_D²² = -44.3 (c = 0.33 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 10.61 min (major) and 12.35 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 7.71 (s, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.07-6.94 (m, 2H), 6.82 (dd, *J* = 14.8, 5.2 Hz, 2H), 6.69 (d, *J* = 8.0 Hz, 1H), 5.78 (s, 1H), 4.37 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.66 (d, *J* = 10.4 Hz, 1H), 3.20 (t, *J* = 10.4 Hz, 1H), 2.83 (q, *J* = 7.2 Hz, 1H), 1.84 (s, 3H), 1.60 (d, *J* = 6.0 Hz, 3H), 1.22 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.1, 179.3, 152.3, 147.2, 143.7, 140.2, 131.1, 129.3, 128.6, 128.3, 126.2, 125.3, 125.1, 122.1, 116.8, 110.0, 50.7, 44.1, 36.5, 34.7, 20.7, 20.7, 18.9. HRMS (ESI-TOF) calcd for C₂₄H₂₃NO₃ [M+Na]⁺ = 396.1570, Found 396.1575.





2,5-dimethyl-2'-oxo-2,4a,5,12c-tetrahydrospiro[dibenzo[c,f]chromene-1,3'indoline]-3-carbaldehyde (5ib)



5ib White solid; 65% yield; >99% ee; 1:4 dr; m.p. 60 °C-62 °C; $[\alpha]_D^{22} = 55.6$ (c = 0.16 in CHCl₃); HPLC (DAICEL CORPORATION AD-H, 2-propanol/*n*-hexane = 20/80, flow rate = 1.0 mL/min, $\lambda = 254$ nm, retention time: 8.20 min (major) and 9.28 min (minor); ¹H NMR (400 MHz, CDCl₃) $\delta = 9.71$ (s, 1H), 7.60-7.50 (m, 2H), 7.33 (t, J = 7.2 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 7.05 (dd, J = 16.0, 8.4 Hz, 4H), 6.72 (d, J = 7.8 Hz, 1H), 6.62 (q, J = 8.4 Hz, 2H), 4.92 (dd, J = 6.4, 4.0 Hz, 1H), 3.66 (dt, J = 12.0, 4.4 Hz, 1H), 3.50-3.44 (m, 1H), 3.17 (d, J = 6.8 Hz, 1H), 1.33 (d, J = 6.8 Hz, 4H), 0.98 (d, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 191.1$, 178.6, 152.3, 151.9, 142.2, 141.8, 134.8, 133.0, 129.3, 129.2, 128.5, 128.0, 124.3, 123.8, 123.2, 122.8, 122.5, 120.1, 114.5, 109.9, 70.7, 56.4, 43.3, 42.5, 41.4, 22.7, 14.1. HRMS (ESI-TOF) calcd for C₂₇H₂₃NO₃ [M+Na]⁺ = 432.1570, Found 432.1585.





5',6,9-trimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8carbaldehyde (5ja)



5ja White solid; 67% yield; 98% ee; 6:1 dr; m.p. 122 °C-124 °C; [α]_D²² = -56.4 (c = 0.69 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 20.85 min (major) and 26.50 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.53 (s, 1H), 8.34 (s, 1H), 7.08 (d, *J* = 8.0 Hz, 1H), 7.03-6.95 (m, 2H), 6.82 (t, *J* = 8.0 Hz, 3H), 6.45 (t, *J* = 7.6 Hz, 1H), 6.03 (d, *J* = 7.6 Hz, 1H), 4.40 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.65 (d, *J* = 10.4 Hz, 1H), 3.20 (t, *J* = 10.4 Hz, 1H), 2.80 (q, *J* = 6.8 Hz, 1H), 2.28 (s, 3H), 1.61 (d, *J* = 6.0 Hz, 3H), 1.20 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.1, 179.9, 154.6, 147.0, 143.9, 137.8, 131.4, 131.0, 128.9, 127.8, 126.6, 126.0, 124.5, 120.5, 117.1, 110.2, 77.7, 50.8, 44.1, 36.5, 34.8, 21.3, 20.8, 19.0. HRMS (ESI-TOF) calcd for C₂₄H₂₃NO₃ [M+Na]⁺ = 396.1570, Found 396.1581.



5'-fluoro-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5ka)



5ka White solid; 80% yield; 96% ee; 6:1 dr; m.p. 109 °C-111 °C; $[\alpha]_D^{22} = -43.7$ (c = 0.35 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 13.96 min (major) and 20.39 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 7.96 (s, 1H), 7.02 (dt, *J* = 8.8, 4.4 Hz, 2H), 6.96-6.87 (m, 2H), 6.88-6.76 (m, 2H), 6.48 (t, *J* = 7.6 Hz, 1H), 6.00 (d, *J* = 7.6 Hz, 1H), 4.40 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.63 (d, *J* = 10.4 Hz, 1H), 3.19 (t, *J* = 10.8 Hz, 1H), 2.84 (q, *J* = 6.8 Hz, 1H), 1.61 (d, *J* = 6.0 Hz, 3H), 1.21 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.8, 179.2, 159.8, 154.6, 146.8, 143.4, 136.1, 132.7, 128.0, 125.5, 124.0, 120.5, 117.3, 115.0, 113.8, 110.8, 92.8, 77.6, 51.2, 44.1, 36.6, 34.8, 20.8, 18.8. HRMS (ESI-TOF) calcd for C₂₃H₂₀FNO₃ [M+Na]⁺ = 400.1319, Found 400.1320.



6'-chloro-6,9-dimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5la)



^{5la} light yellow solid; 90% yield; >99% ee; 7:1 dr; m.p. 139 °C-141 °C; $[\alpha]_D{}^{22} = -29.0$ (c = 1.12 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2-propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, $\lambda = 254$ nm, retention time: 13.96 min (major) and 19.58 min (minor); ¹H NMR (400 MHz, CDCl₃) $\delta = 9.53$ (s, 1H), 8.99 (s, 1H), 7.09-6.92 (m, 4H), 6.84 (dd, J = 12.4, 5.2 Hz, 2H), 6.48 (t, J = 7.6

Hz, 1H), 5.99 (d, J = 7.6 Hz, 1H), 4.40 (dq, J = 12.0, 6.0 Hz, 1H), 3.65 (d, J = 10.4 Hz, 1H), 3.18 (t, J = 10.4 Hz, 1H), 2.80 (q, J = 6.8 Hz, 1H), 1.63 (d, J = 6.0 Hz, 3H), 1.17 (d, J = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 193.0$, 180.1, 154.6, 147.0, 143.5, 141.5, 134.3, 129.4, 128.1, 126.6, 125.6, 124.0, 122.1, 120.6, 117.3, 111.3, 77.7, 50.7, 44.1, 36.4, 34.8, 20.8, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₀ClNO₃ [M+Na]⁺ = 416.1024, Found 416.1023.



1',6,9-trimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'indoline]-8-carbaldehyde (5ma)



5ma White solid; 31% yield; 94% ee; 10:1 dr; m.p. 62 °C-64 °C; $[\alpha]_D^{22}$

= -52.0 (c = 0.10 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 17.80 min (major) and 22.07 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.53 (s, 1H), 7.41 (t, *J* = 7.6 Hz, 1H), 7.28 (s, 1H), 7.08 (t, *J* = 7.6 Hz, 1H), 6.99 (dd, *J* = 7.2, 4.0 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 6.41 (t, *J* = 7.6 Hz, 1H), 5.86 (d, *J* = 7.6 Hz, 1H), 5.02-4.87 (m, 1H), 3.79-3.69 (m, 2H), 3.19 (s, 3H), 2.69 (dd, *J* = 14.0, 6.8 Hz, 1H), 1.42 (d, *J* = 6.4 Hz, 3H), 1.24 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.8, 177.5, 154.9, 146.9, 143.4, 143.2, 130.7, 128.7, 127.9, 125.6, 125.6, 124.2, 122.1, 120.1, 117.2, 108.8, 77.3, 77.2, 77.0, 76.7, 73.5, 58.5, 50.4, 41.4, 34.7, 19.1, 18.4, 17.8. HRMS (ESI-TOF) calcd for C₂₄H₂₃NO₃ [M+Na]⁺ = 396.1570, Found 396.1573.



6,9-dimethyl-2'-oxo-1'-phenyl-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5na)



5na White solid; 45% yield; 92% ee; 12:1 dr; m.p. 72 °C-74 °C; $[\alpha]_D^{22}$

= -25.6 (c = 0.50 in CHCl₃); HPLC (DAICEL CORPORATION AS-H, 2-propanol/*n*-hexane = 3/97, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 32.66 min (major) and 37.55 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 7.49 (t, *J* = 7.6 Hz, 2H), 7.39 (d, *J* = 7.6 Hz, 1H), 7.34 (t, *J* = 6.8 Hz, 4H), 7.10 (t, *J* = 7.2 Hz, 1H), 7.03 (t, *J* = 7.2 Hz, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.83 (d, *J* = 7.6 Hz, 1H), 6.79 (d, *J* = 2.0 Hz, 1H), 6.49 (t, *J* = 7.2 Hz, 1H), 6.14 (d, *J* = 7.6 Hz, 1H), 5.05-4.87 (m, 1H), 3.86-3.74 (m, 2H), 2.91 (q, *J* = 6.8 Hz, 1H), 1.44 (d, *J* = 6.4 Hz, 3H), 1.31 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.8, 177.0, 155.1, 146.8, 143.3, 134.2, 130.4, 129.6, 128.6, 128.2, 128.0, 126.7, 125.9, 125.8, 124.2, 122.6, 120.1, 117.3, 110.1, 73.6, 50.4, 41.5, 34.9, 31.1, 19.0, 17.8. HRMS (ESI-TOF) calcd for C₂₉H₂₅NO₃ [M+Na]⁺ = 458.1727, Found 458.1728.





6',9'-dimethyl-2-oxo-6',6a',9',10a'-tetrahydro-5'H-spiro[indoline-3,10'phenanthridine]-8'-carbaldehyde (50a)



50a light orange solid; 83% yield; >99% ee; 2.5:1 dr; m.p. 121 °C-123 °C; $[α]_D^{22} = -88.8$ (c = 0.55 in CHCl₃); HPLC (DAICEL CORPORATION AD-H), 2-propanol/*n*-hexane = 20/80, flow rate = 1.0 mL/min, λ= 254 nm, retention time: 19.96 min (major) and 17.34 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 8.37 (s, 1H), 7.24 (d, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 7.2 Hz, 1H), 7.00-6.89 (m, 3H), 6.86 (t, *J* = 7.6 Hz, 1H), 6.48 (d, *J* = 7.6 Hz, 1H), 6.21 (t, *J* = 7.6 Hz, 1H), 5.94 (d, *J* = 7.6 Hz, 1H), 3.65-3.46 (m, 2H), 2.92 (t, *J* = 10.0 Hz, 1H), 2.80 (q, *J* = 6.8 Hz, 1H), 1.47 (d, *J* = 6.0 Hz, 3H), 1.18 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.4, 180.2, 149.0, 144.5, 143.3, 140.1, 131.5, 128.3, 127.2, 125.8, 124.1, 123.0, 121.9, 117.0, 113.5, 110.3, 53.8, 51.0, 43.3, 37.8, 35.0, 22.4, 18.9. HRMS (ESI-TOF) calcd for C₂₃H₂₂N₂O₂ [M+Na]⁺ = 381.1573, Found 381.1584.



2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8carbaldehyde (5pa)





°C; $[\alpha]_D^{22} = 14.6$ (c = 0.35 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 20/80, flow rate = 1.0 mL/min, $\lambda = 254$ nm, retention time: 16.65 min (major) and 23.05 min (minor); ¹H NMR (400 MHz, CDCl₃) $\delta = 9.57$ (s, 1H), 8.28 (s, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 7.12 (t, *J* = 7.6 Hz, 1H), 7.06-6.93 (m, 2H), 6.82 (s, 1H), 6.78 (d, *J* = 8.0 Hz, 1H), 6.44 (t, *J* = 7.2 Hz, 1H), 6.18 (d, *J* = 8.0 Hz, 1H), 4.68 (dd, *J* = 10.0, 4.0 Hz, 1H), 4.18-4.07 (m, 1H), 3.95 (t, *J* = 11.2 Hz, 1H), 3.51 (d, *J* = 10.4 Hz, 1H), 2.78 (d, *J* = 18.8 Hz, 1H), 2.65 (d, *J* = 18.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 192.7$, 179.7, 154.8, 146.3, 139.9, 138.3, 134.5, 128.7, 128.4, 125.4, 123.6, 122.9, 122.6, 120.4, 117.1, 110.4, 70.2, 47.5, 41.4, 35.6, 34.4. HRMS (ESI-TOF) calcd for C₂₁H₁₇NO₃ [M+Na]⁺ = 354.1101, Found 354.1103.



6,9-diethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'-indoline]-8-carbaldehyde (5qa)



5qa yellow solid; 60% yield; >99% ee; 3:1 dr; m.p. 53 °C-55 °C; [α]_D²² = -86.3 (c = 0.23 in CHCl₃); HPLC (DAICEL CORPORATION AD-H, 2propanol/*n*-hexane = 5/95, flow rate = 1.0 mL/min, λ = 220 nm, retention time: 22.05 min (major) and 30.51 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.58 (s, 1H), 8.03 (s, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.21 (d, *J* = 7.6 Hz, 1H), 7.00 (dd, *J* = 16.4, 7.6 Hz, 3H), 6.85 (dd, *J* = 13.6, 5.2 Hz, 2H), 6.46 (t, *J* = 7.6 Hz, 1H), 5.99 (d, *J* = 7.6 Hz, 1H), 4.33-4.17 (m, 1H), 3.70 (d, *J* = 10.4 Hz, 1H), 3.19 (t, *J* = 10.0 Hz, 1H), 2.74 (t, *J* = 5.8 Hz, 1H), 2.12-2.03 (m, 1H), 1.93-1.84 (m, 1H), 1.78 (dt, *J* = 14.4, 7.2 Hz, 1H), 1.54-1.45 (m, 1H), 1.17 (t, *J* = 7.2 Hz, 3H), 0.73 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.1, 179.5, 154.9, 147.6, 142.6, 140.1, 131.0, 128.6, 127.8, 126.7, 125.7, 123.9, 122.3, 120.5, 117.2, 110.3, 82.1, 51.2, 42.2, 40.8, 37.6, 27.3, 26.4, 13.1, 9.2. HRMS (ESI-TOF) calcd for C₂₅H₂₅NO₃ [M+Na]⁺ = 410.1727, Found 410.1725.



2'-oxo-6,9-dipropyl-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'indoline]-8-carbaldehyde (5ra)



5ra yellow solid; 78% yield; >99% ee; 4:1 dr; m.p. 129 °C-131 °C; [α]_D²² = -84.7 (c = 0.66 in CHCl₃); HPLC (DAICEL CORPORATION AD-H), 2propanol/*n*-hexane = 7/93, flow rate = 1.0 mL/min, λ = 220 nm, retention time: 13.68 min (major) and 21.51 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.57 (s, 1H), 8.60 (s, 1H), 7.30 (td, *J* = 7.6, 0.8 Hz, 1H), 7.19 (d, *J* = 7.2 Hz, 1H), 7.06-6.93 (m, 3H), 6.83 (t, *J* = 5.6 Hz, 2H), 6.46 (t, *J* = 7.6 Hz, 1H), 5.98 (d, *J* = 7.6 Hz, 1H), 4.39-4.19 (m, 1H), 3.69 (d, *J* = 10.4 Hz, 1H), 3.16 (td, *J* = 10.8, 1.6 Hz, 1H), 2.76 (t, *J* = 5.6 Hz, 1H), 1.99-1.88 (m, 1H), 1.79-1.72 (m, 3H), 1.66-1.55 (m, 1H), 1.46-1.34 (m, 1H), 1.23-1.15 (m, 1H), 1.05 (t, *J* = 7.2 Hz, 4H), 0.96-0.79 (m, 3H), 0.75 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 193.1, 180.3, 154.8, 147.3, 143.1, 140.2, 131.0, 128.6, 127.7, 126.8, 125.4, 124.0, 122.3, 120.6, 117.3, 110.6, 80.9, 51.2, 42.7, 39.9, 37.6, 36.6, 36.0, 22.1, 18.2, 14.2, 14.1. HRMS (ESI-TOF) calcd for C₂₇H₂₉NO₃ [M+Na]⁺ = 438.2040, Found 438.2042.



2,2-dimethyl-4-(2-oxoindolin-3-yl)chroman-3-carbaldehyde (5s)



5s White solid; 55% yield; 87% ee; >20:1 dr; m.p. 95 °C- 97 °C; $[α]_D^{22}$ = 23.6 (c = 0.6 in CHCl₃); HPLC (DAICEL CORPORATION AD-H, 2-propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 28.39 min (major) and 33.70 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.70 (d, *J* = 4.0 Hz, 1H), 8.65 (s, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.20 (dd, *J* = 14.4, 7.2 Hz, 2H), 6.95 (t, *J* = 7.6 Hz, 1H), 6.85 (dd, *J* = 14.4, 7.6 Hz, 3H), 6.33 (d, *J* = 7.2 Hz, 1H), 4.28 (dd, *J* = 10.8, 2.4 Hz, 1H), 4.06 (d, *J* = 2.0 Hz, 1H), 1.36 (s, 3H), 1.24 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 202.2, 178.5, 153.6, 141.5, 128.6, 128.5, 127.4, 126.4, 124.4, 122.9, 121.5, 121.1, 118.2, 110.3, 74.2, 57.1, 49.8, 33.4, 28.1, 21.2. HRMS (ESI-TOF) calcd for C₂₀H₁₉NO₃ [M+Na]⁺=344.1257, Found 344.1248



6,6,9-trimethyl-2'-oxo-6,6a,9,10a-tetrahydrospiro[benzo[c]chromene-10,3'indoline]-8-carbaldehyde (5sa)



5sa White solid; 50% yield; 97% ee; 5:1 dr; m.p. 65 °C-67 °C; $[\alpha]_D^{22}$ = -59.2 (c = 0.31 in CHCl₃); HPLC (DAICEL CORPORATION AS-H, 2-propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 12.13 min (major) and 14.02 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.54 (s, 1H), 8.19 (s, 1H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.19 (d, *J* = 7.2 Hz, 1H), 7.06-6.91 (m, 3H), 6.81 (dd, *J* = 14.4, 5.2 Hz, 2H), 6.49 (t, *J* = 7.6 Hz, 1H), 6.06 (d, *J* = 7.6 Hz, 1H), 3.65 (d, *J* = 10.8 Hz, 1H), 3.25 (d, *J* = 10.8 Hz, 1H), 2.81 (q, *J* = 6.8 Hz, 1H), 1.61 (s, 3H), 1.43 (s, 3H), 1.23 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 192.9, 179.7, 154.5, 147.7, 143.3, 140.1, 131.1, 128.5, 128.0, 127.7, 125.8, 123.8, 122.1, 120.8, 117.7, 110.3, 79.6, 50.7, 48.2, 34.5, 33.0, 28.8, 24.5, 18.8. HRMS (ESI-TOF) calcd for C₂₄H₂₃NO₃ [M+Na]⁺ = 396.1570, Found 396.1576.



6,9-dimethyl-1',3'-dioxo-1',3',6,6a,9,10a-hexahydrospiro[benzo[c]chromene-

10,2'-indene]-8-carbaldehyde (5ta)



5ta White solid; 70% yield; >99% ee; 2: 1 dr; m.p. 220 °C-222 °C; [α]_D²² = -45.3 (c = 0.21 in CHCl₃); HPLC (DAICEL CORPORATION AS-H), 2propanol/*n*-hexane = 10/90, flow rate = 1.0 mL/min, λ = 254 nm, retention time: 21.36 min (major) and 35.74 min (minor); ¹H NMR (400 MHz, CDCl₃) δ = 9.49 (s, 1H), 8.16-8.07 (m, 1H), 7.98-7.86 (m, 3H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.84 (dd, *J* = 15.2, 5.2 Hz, 2H), 6.47 (t, *J* = 7.6 Hz, 1H), 6.23 (d, *J* = 7.6 Hz, 1H), 4.40 (dq, *J* = 12.0, 6.0 Hz, 1H), 3.79 (d, *J* = 10.8 Hz, 1H), 3.25 (t, *J* = 10.8 Hz, 1H), 2.89 (q, *J* = 6.8 Hz, 1H), 1.64 (d, *J* = 6.0 Hz, 3H), 1.16 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ =
200.4, 199.7, 192.6, 154.5, 147.1, 143.7, 141.1, 141.0, 136.1, 136.0, 128.2, 124.4, 124.1, 124.1, 123.9, 120.1, 117.3, 77.6, 56.3, 43.7, 35.9, 33.9, 20.6, 18.0. HRMS (ESI-TOF) calcd for $C_{24}H_{20}O_4$ [M+Na]⁺ = 395.1254, Found 395.1259.



(I) References

 (1) Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies. Sureyya Olgen, Eiichi Akaho, Dogu Nebioglu aS. Olgen et al. / Il Farmaco 60 (2005) 497–506
(2) Synthesis and In Vitro Evaluation of Oxindole Derivatives as Potential Radioligands for 5-HT7 Receptor Imaging with PET Quick ViewFull Text By Herth, Matthias M. et al From ACS Chemical Neuroscience, 3(12), 1002-1007; 2012

(J) Copies of NMR Spectra














































































Bond precision:	C-C = 0.0148 A	Wavelength=1.54184	
Cell:	a=12.9969(4)	b=17.0693(8)	c=23.6874(7)
	alpha=90	beta=90	gamma=90
Temperature:	293 K		
	Calculated	Reported	
Volume	5255.0(3)	5255.0(3)	
Space group	C 2 2 21	C222(1)	

Moiety formula	C23 H19 F N O3, C	H C13	C23 H19 F N O3, C H Cl3
Sum formula	C24 H20 Cl3 F N O3	i i	C24 H20 Cl3 F N O3
Mr	495.76		495.76
Dx,g cm-3	1.253		1.253
Ζ	8		8
Mu (mm-1)	3.421		3.421
F000	2040.0		2040.0
F000'	2054.10		
h,k,lmax	15,20,28		15,20,28
Nref	4718[2615]		4044
Tmin,Tmax	0.696,0.686		0.684,0.705
Tmin'	0.632		
Correction method	d= MULTI-SCAN		
Data completeness= 1.55/0.86		Theta(max)= 67.250	
R(reflections)= 0.1558(2392)		wR2(reflections)= 0.3935(4044)	
S = 1.305		Npar=292	2